perform
retrospect
analysi
blood
sampl
store
sar
outbreak
march
june
depart
microbiolog
chemic
patholog
princ
wale
hospit
hong
kong
patient
initi
diagnosi
probabl
sar
accord
criteria
exposur
viru
subsequ
confirm
laboratori
evid
serolog
convers
sarscov
posit
viral
cultur
andor
posit
sarscov
detect
realtim
pcr
look
earli
prognost
factor
archiv
sampl
collect
first
week
onset
fever
studi
total
archiv
plasma
sampl
avail
collect
first
week
remain
secondweek
sampl
advers
diseas
outcom
defin
either
icu
admiss
death
sarscov
infect
plasma
sampl
preserv
analysi
detail
diseas
cours
result
biochem
hematolog
investig
comorbid
includ
histori
diabet
chronic
lung
diseas
hypertens
cerebrovascular
accid
cancer
ischem
heart
diseas
chronic
renal
failur
chronic
liver
diseas
retriev
patient
clinic
note
patient
treat
accord
standard
protocol
detail
elsewher
studi
approv
institut
hospit
research
ethic
committe
measur
panel
inflammatori
cytokin
chemokin
cytometr
bead
array
use
facscalibur
flow
cytomet
becton
dickinson
sampl
process
assay
perform
insid
biosafeti
level
laboratori
cytometr
bead
array
allow
measur
analyt
assay
assay
bead
popul
distinct
fluoresc
properti
coat
differ
captur
antibodi
specif
cytokin
chemokin
incub
patient
sampl
phycoerythrinconjug
detect
antibodi
use
form
sandwich
complex
fluoresc
data
acquir
flow
cytomet
concentr
chemokin
mig
regul
upon
activ
normal
cell
express
secret
rant
measur
analyt
perform
assay
refer
interv
describ
previous
studi
postmortem
lung
tissu
specimen
collect
time
sar
outbreak
patient
die
sar
infect
comparison
patient
whose
death
unrel
sar
infect
pulmonari
patholog
revers
transcript
realtim
quantit
pcr
perform
assay
express
rna
sampl
lung
tissu
extract
rneasi
mini
kit
qiagen
rna
sampl
reversetranscrib
iii
revers
transcriptas
invitrogen
rel
express
gene
lung
sampl
determin
quantit
pcr
system
appli
biosystem
present
rel
express
express
housekeep
gene
sequenc
primer
follow
forward
aag
gcc
atc
aag
aat
revers
ccc
ctc
tgg
ttt
taa
forward
gga
gaa
gct
gtg
cta
cgt
revers
gtt
gaa
ggt
agt
ttc
gtg
immunohistochem
stain
r
system
also
perform
paraffin
section
deparaffin
subject
antigen
retriev
microwav
heat
edta
buffer
mll
appli
block
endogen
peroxidas
follow
rins
incub
casblock
zyme
nonspecif
block
overnight
incub
antibodi
dilut
section
wash
horseradish
peroxidas
polym
conjug
ad
signal
detect
liquid
dab
substrat
kit
zyme
plasma
concentr
analyt
follow
gaussian
distribut
use
nonparametr
utest
compar
concentr
analyt
group
patient
favor
outcom
vs
advers
outcom
associ
categor
variabl
perform
fisher
exact
test
condit
logist
regress
use
identifi
independ
predictor
advers
diseas
outcom
determin
adjust
odd
ratio
risk
factor
perform
logist
regress
analysi
normal
chemokin
plasma
concentr
convers
multipl
median
mom
use
mom
enabl
futur
applic
laboratori
use
differ
assay
analyt
reflect
clinic
scenario
develop
logist
regress
model
variabl
avail
first
week
second
week
fever
onset
specif
variabl
would
avail
specif
time
point
enter
multivari
logist
model
identifi
independ
prognost
featur
statist
roc
analys
perform
spss
spss
inc
archiv
blood
sampl
collect
patient
median
rang
age
year
sixtythre
percent
femal
fortyon
patient
male
femal
advers
outcom
defin
patient
advers
outcom
older
median
interquartil
rang
iqr
year
patient
year
major
firstweek
sampl
sampl
collect
day
onset
fever
median
plasma
concentr
mig
rant
ngl
respect
tabl
increas
plasma
concentr
occur
frequent
patient
follow
rant
secondweek
sampl
sampl
collect
day
onset
fever
plasma
concentr
second
week
significantli
lower
first
week
p
utest
patient
respect
increas
concentr
chemokin
patient
increas
rant
concentr
patient
increas
plasma
ld
activ
admiss
median
iqr
ul
upper
refer
limit
ul
fig
group
patient
favor
advers
outcom
show
increas
trend
ld
first
week
onset
howev
patient
advers
outcom
much
higher
ld
concentr
total
lymphocyt
count
absolut
neutrophil
count
follow
similar
trend
increas
notic
second
week
patient
advers
outcom
significantli
higher
count
time
point
absolut
lymphocyt
count
show
downward
trend
diseas
progress
patient
advers
outcom
significantli
lower
count
day
lymphocyt
count
group
differ
admiss
howev
univari
analysi
show
signific
differ
group
patient
routin
clinic
laboratori
valu
fig
among
item
past
medic
histori
investig
histori
cerebrovascular
accid
associ
poor
diseas
outcom
p
fisher
exact
test
preval
prior
stroke
among
patient
sever
diseas
among
patient
favor
outcom
first
week
onset
fever
concentr
chemokin
mig
differ
patient
favor
advers
outcom
group
thu
chemokin
potenti
prognost
marker
tabl
first
week
increas
concentr
time
median
ngl
associ
odd
ratio
confid
interv
p
subsequ
deterior
lead
advers
outcom
howev
second
week
increas
concentr
one
chemokin
mig
associ
poor
diseas
outcom
univari
analysi
identifi
independ
predictor
advers
diseas
outcom
logist
regress
model
develop
first
secondweek
biochem
marker
chemokin
ld
concentr
follow
gaussian
distribut
normal
mom
multipl
upper
refer
valu
respect
day
day
routin
laboratori
result
also
enter
correspond
logist
regress
model
result
logist
regress
model
shown
tabl
among
variabl
result
avail
first
week
risk
factor
advers
outcom
identifi
patient
age
plasma
ld
concentr
admiss
absolut
neutrophil
count
admiss
plasma
concentr
first
week
interestingli
variabl
use
predictor
later
cours
diseas
result
laboratori
investig
day
avail
time
plasma
ld
concentr
day
absolut
neutrophil
count
day
import
predict
factor
advers
diseas
outcom
tabl
roc
analysi
firstweek
plasma
concentr
confirm
clinic
util
marker
predict
diseas
outcom
area
curv
significantli
p
fig
specif
firstweek
plasma
concentr
provid
sensit
identif
patient
subsequ
advers
clinic
outcom
result
suggest
concentr
could
use
clinic
triag
patient
activ
intervent
respiratori
failur
import
featur
fatal
sar
infect
postmortem
find
patient
describ
previous
brief
lung
show
diffus
alveolar
damag
pulmonari
edema
hyalin
membran
format
focal
hemorrhag
seen
case
express
gene
significantli
increas
p
postmortem
lung
tissu
collect
sar
patient
compar
lung
tissu
specimen
nonsar
patient
autopsi
lung
tissu
patient
lethal
sar
rel
express
index
normal
mrna
lung
tissu
nonsar
patient
immunohistochem
stain
also
confirm
enhanc
protein
product
pneumocyt
alveolar
macrophag
lung
tissu
sar
patient
fig
challeng
sar
infect
gener
worldwid
medic
respons
viru
well
character
genom
scale
laboratori
diagnosi
streamlin
rapid
diagnosi
within
h
onset
fever
achiev
blood
revers
transcriptionpcr
assay
pathogenesi
organ
damag
determin
diseas
outcom
howev
still
well
understood
although
major
sar
patient
recov
treatment
develop
ard
requir
invas
mechan
ventil
histopatholog
examin
lung
specimen
sar
victim
reveal
featur
diffus
alveolar
damag
mark
pulmonari
edema
hyalin
membran
format
intraalveolar
organ
interstiti
thicken
mild
moder
fibrosi
featur
later
stage
featur
bronchiol
obliteransorgan
pneumonialik
lesion
also
note
patient
histolog
find
signifi
dysregul
immun
reaction
key
compon
sarsinduc
pulmonari
lesion
cytokin
particularli
chemokin
key
mediat
recruit
leukocyt
inflammatori
cell
lead
pulmonari
damag
implic
pathogenesi
ardsdiffus
alveolar
damag
previou
studi
show
plasma
concentr
sever
chemokin
includ
significantli
increas
sar
infect
wherea
cytokin
tumor
necrosi
increas
small
proport
patient
product
chemokin
studi
ard
secondari
etiolog
commonli
studi
chemokin
found
increas
bronchoalveolar
lavag
fluid
system
circul
onset
ard
report
suggest
chemokin
concentr
bronchoalveolar
lavag
fluid
andor
blood
predict
outcom
ard
studi
investig
cytokinechemokin
respons
sar
infect
zhang
et
al
studi
serum
cytokin
concentr
sar
patient
symptomat
period
day
confirm
mani
classic
cytokin
tumor
necrosi
increas
sar
infect
chang
serum
cytokin
concentr
occur
sarscov
viru
load
throat
peak
indic
cytokin
mediat
induct
lung
system
inflamm
studi
patient
jiang
et
al
found
markedli
increas
sar
patient
confirm
express
lung
tissu
recent
studi
huang
et
al
tri
correl
univari
analysi
clinic
outcom
chemokin
concentr
sampl
patient
although
higher
concentr
mig
associ
advers
clinic
cours
adjust
establish
clinic
variabl
includ
age
plasma
ld
concentr
import
prognost
factor
studi
shown
mig
significantli
increas
earli
phase
sar
infect
addit
increas
plasma
concentr
mig
first
week
fever
onset
associ
poor
clinic
outcom
tabl
similarli
high
concentr
first
week
also
associ
advers
outcom
interestingli
univari
analysi
show
increas
mig
chemokin
associ
poor
clinic
outcom
second
week
control
prognost
factor
first
week
independ
predict
factor
advers
outcom
mig
lymphocytetarget
cxc
chemokin
act
common
receptor
produc
high
concentr
activ
bronchial
epitheli
cell
respons
infect
activ
cxc
cascad
implic
etiolog
bronchiol
obliteran
syndrom
lung
transplant
lymphocyt
alveol
aid
pulmonari
fibrosi
sarscov
infect
suscept
mice
also
induc
product
mig
togeth
receptor
suggest
key
particip
cascad
sarcov
infect
mice
also
confirm
high
concentr
mrna
protein
lung
specimen
sar
patient
sever
studi
report
routin
laboratori
find
predict
advers
clinic
outcom
sar
infect
studi
confirm
age
plasma
ld
concentr
admiss
absolut
neutrophil
count
independ
predictor
advers
outcom
predictor
consist
identifi
differ
group
studi
differ
patient
cohort
addit
first
time
note
high
concentr
first
week
ill
independ
risk
factor
advers
outcom
prognost
indic
readili
applic
clinic
set
earli
marker
measur
within
first
week
ill
hand
secondweek
chemokin
concentr
provid
inform
addit
provid
ld
activ
neutrophil
count
obtain
day
persist
increas
ld
activ
first
week
may
best
indic
poor
outcom
might
also
fairli
obviou
clinic
statu
moment
futur
applic
particularli
laboratori
use
assay
median
concentr
determin
whole
group
patient
sar
patient
patient
increas
median
would
increas
risk
advers
outcom
summari
identifi
prognost
factor
detect
within
first
week
onset
sar
symptom
high
concentr
independ
indic
poor
prognosi
overexpress
chemokin
cascad
appear
play
import
role
integr
immun
respons
sarscov
subsequ
intens
immun
reaction
associ
extens
parenchym
damag
advers
clinic
outcom
abbrevi
sar
sever
acut
respiratori
syndrom
cov
coronaviru
icu
intens
care
unit
ard
acut
respiratori
distress
syndrom
il
interleukin
mig
monokin
monocyt
chemoattract
ld
lactat
dehydrogenas
rant
regul
upon
activ
normal
cell
express
secret
mom
multipl
median
iqr
interquartil
rang
